Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

luspatercept

(lus-PA-ter-cept)
A drug used to treat anemia in adults with certain types of myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms who need regular red blood cell transfusions and whose anemia did not respond to or cannot be treated with an erythropoiesis-stimulating agent. Luspatercept is also used to treat anemia in adults with beta thalassemia (an inherited blood disorder) who need regular red blood cell transfusions. It is also being studied in the treatment of other conditions. Luspatercept helps the bone marrow make more red blood cells. It is a type of antianemic and a type of recombinant fusion protein. Also called Reblozyl.
More Information
Search NCI's Dictionary of Cancer Terms